Esperion Therapeutics Inc (ESPR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have been assigned an average recommendation of “Buy” from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $75.96.

A number of equities research analysts have issued reports on the stock. ValuEngine upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Northland Securities upgraded shares of Esperion Therapeutics from a “market perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research note on Monday, October 29th. Cowen set a $82.00 price objective on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research note on Friday, October 26th. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. Finally, BTIG Research assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, October 16th. They set a “buy” rating and a $82.00 price objective on the stock.

In other news, Director Roger S. Newton sold 9,400 shares of the firm’s stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $50.01, for a total value of $470,094.00. Following the sale, the director now directly owns 589,326 shares in the company, valued at approximately $29,472,193.26. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Roger S. Newton sold 2,827 shares of the firm’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $50.07, for a total transaction of $141,547.89. Following the completion of the sale, the director now owns 573,953 shares in the company, valued at $28,737,826.71. The disclosure for this sale can be found here. Insiders have sold 37,327 shares of company stock worth $1,885,665 over the last quarter. Corporate insiders own 14.50% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of ESPR. Xact Kapitalforvaltning AB acquired a new stake in shares of Esperion Therapeutics in the 1st quarter valued at approximately $250,000. Keybank National Association OH boosted its stake in shares of Esperion Therapeutics by 97.7% in the 2nd quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 3,787 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Esperion Therapeutics by 40.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 2,224 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at approximately $333,000. Finally, Creative Planning boosted its stake in shares of Esperion Therapeutics by 42.0% in the 3rd quarter. Creative Planning now owns 7,562 shares of the biopharmaceutical company’s stock valued at $336,000 after purchasing an additional 2,236 shares in the last quarter.

NASDAQ:ESPR traded up $3.15 during mid-day trading on Monday, reaching $59.03. 57,101 shares of the company’s stock were exchanged, compared to its average volume of 921,904. Esperion Therapeutics has a one year low of $33.06 and a one year high of $82.68. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -8.47 and a beta of 2.20.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.22). During the same period last year, the company earned ($1.86) EPS. As a group, analysts anticipate that Esperion Therapeutics will post -6.31 EPS for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Story: The risks of owning bonds

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply